Japanese Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Corrigendum to: Feasibility of next-generation sequencing (Oncomine ™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients
In the originally published version of this manuscript, corresponding author Tatsuya Yoshida's address should read: ``Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, 5-1-1 Tsukiji, Chuo, Tokyo 104-0051, Japan. E-mail: tatyoshi@ncc.go.jp and first author Yuki Takeyasu's address should read ``Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo 104-0051, Japan. E-mail: ytakeyas@ncc.go.jp, Tel: 03-3542-2511, Fax: 03-3545-3567. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 8, 2021 Category: Cancer & Oncology Source Type: research

Imaging features of Carney complex with external auditory canal myxoma
Figure 1.(A and B, arrows) Axial magnetic resonance (MR) and computed tomography (CT) images showing the soft tissue nodule in the left external auditory canal from a histologically proven myxoma. (C) Corresponding surgical specimen of the myxoma from (A and B). (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 4, 2021 Category: Cancer & Oncology Source Type: research

Surgical upstaging rates in patients meeting the eligibility for active surveillance trials
ConclusionsThe upstaging rate in patients eligible for the clinical active surveillance trials was 12 –25%. Although the rate of upstaging to pT1b or higher was low, further studies are required to determine the rates of upstaging to invasive cancer and the risk factors among patients with low-risk ductal carcinomain situ. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 4, 2021 Category: Cancer & Oncology Source Type: research

Prognostic significance of the controlling nutritional status score in patients with metastatic renal cell carcinoma diagnosed before an era of first-line immune-oncology combination therapies
ConclusionThe controlling nutritional status score may serve as a prognostic biomarker objectively reflecting the general physical condition of patients with metastatic renal cell carcinoma treated with or without first-line interferon or tyrosine kinase inhibitor in terms of nutritional and immuno-inflammatory status. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - June 1, 2021 Category: Cancer & Oncology Source Type: research

Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
ConclusionsThis large-scale, real-world, post-marketing surveillance study confirmed the safety and efficacy of abiraterone acetate plus prednisolone in Japanese castration-resistant prostate cancer patients with or without previous chemotherapy. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 29, 2021 Category: Cancer & Oncology Source Type: research

Smaller decline of renal function after nephroureterectomy predicts poorer prognosis of upper tract urothelial carcinoma: a multicentre retrospective study
ConclusionsLower preoperative renal function, especially of the affected side kidney, was significantly associated with poor prognosis after nephroureterectomy for upper tract urothelial carcinoma. Many patients with locally advanced disease have reduced renal function at diagnosis and even more after surgery. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 28, 2021 Category: Cancer & Oncology Source Type: research

Clinical benefits of vessel sealing system (LigaSure ™) during surgery for soft tissue sarcoma: a propensity score matching analysis
ConclusionBy using LigaSure ™ for soft tissue sarcomas occurring in the buttocks and lower extremities, we observed a trade-off between reduced intraoperative blood loss and longer operative time. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 28, 2021 Category: Cancer & Oncology Source Type: research

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
AbstractNeuroendocrine neoplasms (NENs) constitute a heterogeneous group of tumors. In this review, we summarize the results of various clinical trials that have been conducted to investigate the efficacy and safety of various therapeutic options for NENs. Based on the encouraging results obtained from these trials, various therapeutic options have been established for the treatment of NENs, including somatostatin analogs (SSAs), molecularly targeted drugs and cytotoxic agents. In addition, peptide receptor radionucleotide therapy has recently been evaluated for the treatment of various NENs. We also discuss the approach f...
Source: Japanese Journal of Clinical Oncology - May 27, 2021 Category: Cancer & Oncology Source Type: research

Age-specific testis cancer incidence rate in the world
To make a comparison of the age-specific testis cancer incidence rate between Japan and other countries, we abstracted cancer incidence rate from the Cancer Incidence in Five Continents Vol. XI (CI5) (1). The International Agency for Research on Cancer provides the CI5 databases on the incidence of cancer recorded by cancer registries (regional and national) worldwide. We used cancer incidence rate in five countries in Asia (China, India, Japan, Republic of Korea and Thailand), three countries in America (the USA, Canada and Brazil), two countries in Oceania (Australia and New Zealand), and four countries in Europe (the UK...
Source: Japanese Journal of Clinical Oncology - May 26, 2021 Category: Cancer & Oncology Source Type: research

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
ConclusionsTepotinib demonstrated robust and durable clinical efficacy in Japanese patients with advanced NSCLC harbouringMET exon 14 skipping, identified by either liquid or tissue biopsy. The main adverse events, blood creatinine increase and peripheral oedema, were manageable. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 25, 2021 Category: Cancer & Oncology Source Type: research

Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
ConclusionsWe successfully established a reliable signature for predicting early relapse in stage I –III non-small cell lung cancer. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 25, 2021 Category: Cancer & Oncology Source Type: research

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-na ïve metastatic castration-resistant prostate cancer in Japan
ConclusionsResults modeled herein suggest that the enzalutamide-first sequencing is more cost-effective than the abiraterone-first sequencing, but less cost-effective than docetaxel-first sequencing for chemotherapy-na ïve patients with metastatic castration-resistant prostate cancer. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 25, 2021 Category: Cancer & Oncology Source Type: research

Prospective evaluation of watchful waiting for early-stage lung cancer with ground-glass opacity: a single-arm confirmatory multicenter study: Japan Clinical Oncology Group study JCOG1906 (EVERGREEN study)
AbstractAmong early-stage lung cancers that show ground-glass nodules on chest computed tomography, the lung cancer surgical study group of the Japan Clinical Oncology Group previously reported that nodules of ≤2 cm with a consolidation/tumor ratio of ≤0.25 were considered radiologically non-invasive cancers with a low risk of metastasis. However, there is no consensus based on high-quality evidence about the optimal timing of surgical intervention for radiologically non-invasive cancers. In June 2020 , we launched a multi-institutional, single-arm confirmatory trial to evaluate the efficacy and safety of watchful wait...
Source: Japanese Journal of Clinical Oncology - May 21, 2021 Category: Cancer & Oncology Source Type: research

Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
ConclusionWe demonstrated the efficacy of palonosetron in pediatric patients receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy and confirmed the appropriateness of the 20  μg/kg dose, regardless of age, considering the safety and pharmacokinetic profiles.Trial registrationJapicCTI-163305, registered 6 June 2016. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 21, 2021 Category: Cancer & Oncology Source Type: research

Prognostic role of interstitial pneumonia with or without emphysema in patients with clinical stage I lung cancer
ConclusionsThe presence of emphysema was not an independent prognostic factor for overall survival in patients with clinical stage I lung cancer with interstitial pneumonia. Poor survival of patients with IP and emphysema may be due to the presence of interstitial pneumonia. (Source: Japanese Journal of Clinical Oncology)
Source: Japanese Journal of Clinical Oncology - May 18, 2021 Category: Cancer & Oncology Source Type: research